The Fridley, Minn.-based company’s Kyphon HV-R bone cement is now indicated for treating pathological fractures of the vertebral body due to osteoporosis, cancer or benign lesions using a cementoplasty procedure.
The cement is also indicated for the fixation of pathological fractures of the sacral vertebral body or ala using sacral vertebroplasty or sacroplasty, the company said.
“Patients who experience sacral insufficiency fractures often suffer a substantial degree of pain and disability. This new indication for Kyphon HV-R cement, along with Kyphon Xpede bone cement will provide another excellent option to help these patients,” Dr. Thomas Andreshak of Maumee, Ohio’s Mercy St. Vincent Medical Center and St. Luke’s Hospital said in a prepared statement.
“Early intervention is an important consideration for both hospital costs and patient outcomes. Combined with our 20 years of experience in vertebral compression fractures, this new indication for our bone cement solution allows us to continue to make an impact on vertebral compression fracture and sacral insufficiency diagnosis treatment in the U.S. by giving physicians options to deliver the best clinical solutions to their patients,” Medtronic interventional pain therapies biz GM Jeff Cambra said in a press release
Earlier this month, Medtronic said it won FDA approval for its Deep Brain Stimulation clinician programmer and Activa programming application.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.